AstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded UseZacks Investment Research • 10/01/24
AstraZeneca PLC (AZN) Annual Deutsche Bank Leveraged Finance Conference (Transcript)Seeking Alpha • 09/24/24
AstraZeneca Stock Falls After Disappointing Results in Breast Cancer Drug TrialInvestopedia • 09/23/24
AstraZeneca's experimental cancer drug shows no significant improvement in overall survivalReuters • 09/23/24
Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 TrialBusiness Wire • 09/23/24
Wall Street Bulls Look Optimistic About Astrazeneca (AZN): Should You Buy?Zacks Investment Research • 09/19/24
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market AgainThe Motley Fool • 09/19/24
AstraZeneca PLC (AZN) Meet the Management at ESMO 2024 Conference (Transcript)Seeking Alpha • 09/17/24
ENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastasesBusiness Wire • 09/13/24
Moffitt Cancer Center Announces Strategic Collaboration with AstraZeneca to Accelerate Oncology Cell TherapiesBusiness Wire • 09/13/24